



5951 E. Mayo Boulevard
Phoenix, AZ 85054
904-953-7904
Tax ID: 86-0800150

June 9, 2026

Dear Exhibitor,

On behalf of the Mayo Clinic School of Continuous Professional Development and Course Directors course directors Chadi Ayoub, M.B.B.S., Ph.D., Joerg Herrmann, M.D., Lida A. Mina, M.D. Chris Ray, M.D., Balaji Tamarappoo, M.D., Ph.D. and Surbhi Shah, M.B.B.S., we hope you will consider a display opportunity at the **Mayo Clinic Cardio-Oncology Update 2026** that will take place **November 12-15, 2026**, at the Caesars Republic Scottsdale, Scottsdale, Arizona. We expect approximately 100 in person attendees comprised of general cardiologists, heart failure specialists, and advanced practice providers working in cardiology who either currently practice cardio-oncology or aim to expand their practice into the field to optimize the care of this patient population. The course is also designed for providers in hematology, oncology, and internal medicine as they are often the first to encounter and diagnose patients with cardiotoxicity related to cancer therapies.

This course reviews the prevention, diagnosis, and management of cardiac and vascular diseases of cancer patients throughout the continuum of their care including heart failure, myocardial ischemia, hypertension, thromboembolism, and arrhythmia. It is directed towards the spectrum of providers who care for cancer patients to enable them to recognize the cardiovascular risk of their patients and take action to minimize this risk. This includes physicians, advanced practice providers, pharmacists, and nurses in cardiology, hematology-oncology, primary care, and hospital internal medicine. The course includes lectures from experts as well as interactive case-based and question and answer sessions.

To maintain a clear separation of promotion from education, all exhibits will be held in a different room/location than where the general sessions are held. Exhibits are open from registration until the conclusion of the final lecture on the last day. Display space is limited, and table assignments will be made on a first come, first served basis.

To sign up as an exhibitor or sponsor at this activity please visit the **Mayo Clinic Cardio-Oncology Update 2026- Exhibitor Letter of Agreement** at: <https://ce.mayo.edu/content/mayo-clinic-cardio-oncology-update-2026-exhibitor-letter-agreement>

Choose Your Sponsorship Level

Exhibit fees begin at \$4,000 for the full course. Additional advertisement opportunities are offered to expand reach and provide further interaction with attendees. Exhibit space at the live course is limited.

Please review Sponsorship Opportunities and Additional Advertisement Opportunities on page 3 of this prospectus for full pricing and details.

Exhibit Benefits:

- Promotion available at the live four-day course
- Exhibitors are provided with the same meals and beverages provided to registered attendees
- Attendees are encouraged daily by the course moderator to visit and connect with the exhibitors
- Includes a 6ft table, two chairs and linen at the course
- An attendee list including registered attendee's name, degree, specialty, city, state, and demographics distributed post course

- Vendor recognition in online course syllabus for all registered attendees to access
- An acknowledgement on the break slide announcements during the course

Mayo Clinic, an integrated, not-for-profit group practice, is committed to meeting its responsibility as a national medical education resource. In support of improving patient care, Mayo Clinic College of Medicine and Science is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team. Our programs provide valuable information on unmet needs to the medical community. We sincerely appreciate your consideration and hope you will take the opportunity to join us for a truly unique educational program.

Sincerely,

A handwritten signature in black ink that reads "Karen Steele". The signature is written in a cursive, flowing style.

Karen Steele
Education Administration Coordinator



Additional Advertisement Opportunities:

Lunch Non-CME Product Theatre - \$15,000 (Limited opportunities)

These non-accredited programs, independently developed and directly sponsored by industry, are presented in an educational format that will provide insight on new or controversial developments. Product theatre may not conflict with course content. (Does Not Include audio/visual equipment - No CME credit.) Participating companies are responsible for audio/visual equipment fees.

Breakfast Non-CME Product Theatre - \$12,000 (Limited opportunities)

These non-accredited programs, independently developed and directly sponsored by industry, are presented in an educational format that will provide insight on new or controversial developments. Product theatre may not conflict with course content. (Does Not Include audio/visual equipment - No CME credit.) Participating companies are responsible for audio/visual equipment fees.

Conference Bags - \$3,000 – (Exclusive)

Display your company logo for all attendees to see and announce your presence at the conference. Your company will provide a high-resolution logo to be printed on conference bags ordered by managing committee. All bags will contain flyers and advertisements from other participants. (Artwork to be provided by sponsoring company and is subject to MCSCPD approval)

Conference Bag Inserts - \$1,500 each (Multiple opportunities available)

Conference bag inserts are a great opportunity to invite attendees to your booth, announce your booth participation or share product details with attendees. Your company will provide copies of the flyer or advertisement (no larger than 8 ½ x 11, no more than one page) and the MCSCPD will stuff them into the official conference bags. A limited number of bag inserts are permitted, so early reservation is encouraged. Artwork is subject to MCSCPD approval. (Quantity of fliers/advertisements to be determined 60 days before course.)

Internet - \$5,000 (Exclusive)

Help attendees stay connected with their office and home while away at Mayo Clinic Cardio-Oncology Update 2026. Sponsor the wireless internet access in the meeting space. The supporter will be recognized throughout the meeting in signage and electronic communications.

Lanyards - \$2,000 (Exclusive)

All attendee badges will be distributed with a lanyard to display the badge throughout the conference. The Lanyard will prominently display your company name and/or logo, whichever you choose. (Artwork to be provided by sponsoring company and is subject to MCSCPD approval)

If you have additional sponsorship opportunity ideas that aren't mentioned above, please contact Karen Steele at steele.karen@mayo.edu to discuss.

Request for Taxpayer Identification Number and Certification

Go to www.irs.gov/FormW9 for instructions and the latest information.

Give form to the
requester. Do not
send to the IRS.

Before you begin. For guidance related to the purpose of Form W-9, see *Purpose of Form*, below.

Print or type. See Specific Instructions on page 3.	1 Name of entity/individual. An entry is required. (For a sole proprietor or disregarded entity, enter the owner's name on line 1, and enter the business/disregarded entity's name on line 2.) Mayo Clinic Arizona	
	2 Business name/disregarded entity name, if different from above.	
	3a Check the appropriate box for federal tax classification of the entity/individual whose name is entered on line 1. Check only one of the following seven boxes. ☐ Individual/sole proprietor ☐ C corporation ☐ S corporation ☐ Partnership ☐ Trust/estate ☐ LLC. Enter the tax classification (C = C corporation, S = S corporation, P = Partnership) _____ Note: Check the "LLC" box above and, in the entry space, enter the appropriate code (C, S, or P) for the tax classification of the LLC, unless it is a disregarded entity. A disregarded entity should instead check the appropriate box for the tax classification of its owner. ☒ Other (see instructions) 501 (c) (3) Tax-exempt Nonprofit Corporation	4 Exemptions (codes apply only to certain entities, not individuals; see instructions on page 3): Exempt payee code (if any) 1 Exemption from Foreign Account Tax Compliance Act (FATCA) reporting code (if any) A (Applies to accounts maintained outside the United States.)
	3b If on line 3a you checked "Partnership" or "Trust/estate," or checked "LLC" and entered "P" as its tax classification, and you are providing this form to a partnership, trust, or estate in which you have an ownership interest, check this box if you have any foreign partners, owners, or beneficiaries. See instructions ☐	
	5 Address (number, street, and apt. or suite no.). See instructions. 13400 East Shea Boulevard	Requester's name and address (optional)
6 City, state, and ZIP code Scottsdale, AZ 85259		
7 List account number(s) here (optional)		

Part I Taxpayer Identification Number (TIN)

Enter your TIN in the appropriate box. The TIN provided must match the name given on line 1 to avoid backup withholding. For individuals, this is generally your social security number (SSN). However, for a resident alien, sole proprietor, or disregarded entity, see the instructions for Part I, later. For other entities, it is your employer identification number (EIN). If you do not have a number, see *How to get a TIN*, later.

Note: If the account is in more than one name, see the instructions for line 1. See also *What Name and Number To Give the Requester* for guidelines on whose number to enter.

Social security number									
			-				-		
or									
Employer identification number									
8	6		-	0	8	0	0	1	5
									0

Part II Certification

Under penalties of perjury, I certify that:

- The number shown on this form is my correct taxpayer identification number (or I am waiting for a number to be issued to me); and
- I am not subject to backup withholding because (a) I am exempt from backup withholding, or (b) I have not been notified by the Internal Revenue Service (IRS) that I am subject to backup withholding as a result of a failure to report all interest or dividends, or (c) the IRS has notified me that I am no longer subject to backup withholding; and
- I am a U.S. citizen or other U.S. person (defined below); and
- The FATCA code(s) entered on this form (if any) indicating that I am exempt from FATCA reporting is correct.

Certification instructions. You must cross out item 2 above if you have been notified by the IRS that you are currently subject to backup withholding because you have failed to report all interest and dividends on your tax return. For real estate transactions, item 2 does not apply. For mortgage interest paid, acquisition or abandonment of secured property, cancellation of debt, contributions to an individual retirement arrangement (IRA), and, generally, payments other than interest and dividends, you are not required to sign the certification, but you must provide your correct TIN. See the instructions for Part II, later.

Sign Here	Signature of U.S. person <i>Katy Domaille</i>	Date <i>1/2/2026</i>
------------------	--	-------------------------

General Instructions

Section references are to the Internal Revenue Code unless otherwise noted.

Future developments. For the latest information about developments related to Form W-9 and its instructions, such as legislation enacted after they were published, go to www.irs.gov/FormW9.

What's New

Line 3a has been modified to clarify how a disregarded entity completes this line. An LLC that is a disregarded entity should check the appropriate box for the tax classification of its owner. Otherwise, it should check the "LLC" box and enter its appropriate tax classification.

New line 3b has been added to this form. A flow-through entity is required to complete this line to indicate that it has direct or indirect foreign partners, owners, or beneficiaries when it provides the Form W-9 to another flow-through entity in which it has an ownership interest. This change is intended to provide a flow-through entity with information regarding the status of its indirect foreign partners, owners, or beneficiaries, so that it can satisfy any applicable reporting requirements. For example, a partnership that has any indirect foreign partners may be required to complete Schedules K-2 and K-3. See the Partnership Instructions for Schedules K-2 and K-3 (Form 1065).

Purpose of Form

An individual or entity (Form W-9 requester) who is required to file an information return with the IRS is giving you this form because they



School of Continuous
Professional
Development

Mayo Clinic Cardio- Oncology Update 2026



November 12-15, 2026

MAKE PLANS TO ATTEND

Caesars Republic Scottsdale, a Hilton Hotel
Scottsdale, Arizona



Register today!

ce.mayo.edu/cardiooncupdate2026



21.25 AMA
Category 1 Credit™
21.25 ANCC
21.25 ACPE
21.25 Attendance

COURSE HIGHLIGHTS

This course reviews the prevention, diagnosis, and management of cardiac and vascular diseases of cancer patients throughout the continuum of their care including heart failure, myocardial ischemia, hypertension, thromboembolism, and arrhythmia. The course is directed towards the spectrum of providers who care for cancer patients to enable them to recognize the cardiovascular risk of their patients and take action to minimize this risk. This includes physicians, advance practice providers, pharmacists, and nurses in cardiology, hematology-oncology, primary care, and hospital internal medicine. The course includes lectures from experts as well as interactive case-based and question and answer sessions.

TARGET AUDIENCE

This course is designed for general cardiologists, heart failure specialists, and advanced practice providers working in cardiology who either currently practice cardio-oncology or aim to expand their practice into the field to optimize the care of this patient population. The course is also designed for providers in hematology, oncology, and internal medicine as they are often the first to encounter and diagnose patients with cardiotoxicity related to cancer therapies.

LEARNING OBJECTIVES

- Develop an approach to the prevention of cancer therapeutics related cardiotoxicity
- Summarize guideline based cardiovascular surveillance during cancer therapy associated with a risk of cardiovascular toxicity
- Identify an approach to the integration of multimodality imaging into the cardio-oncology practice
- Review advances in the management of TTR and AL cardiac amyloidosis

- Identify key diagnostic modalities for early detection of cardiac toxicity in cancer patients
- Review current therapeutic interventions for carcinoid valvular heart disease
- Assess the cardiovascular risk profile of individuals diagnosed with prostate cancer
- Recognize unique risk factors for hypertension in cancer patients, including treatment-related factors and comorbidities
- Develop an approach to the management of cancer therapeutics related cardiotoxicity

LODGING & ACCOMMODATIONS

Caesars Republic Scottsdale, a Hilton Hotel
Scottsdale, Arizona

The Caesars Republic Scottsdale, a Hilton Hotel is offering hotel rooms for attendees and their guests at the group rate of \$374 per night plus applicable fees and taxes. Self parking is available for \$28 per night, and valet parking for \$40 per night.

Reservations must be made by October 23, 2026 or before the room block is filled, whichever comes first.

To make online reservations see the Location tab of the course website at ce.mayo.edu/cardiooncupdate2026.

REGISTRATION FEES

	On or before 10/12/26	Full Price
Registration Fees		
M.D., D.O., Ph.D.	\$950	\$1,025
Allied Health, NP, PA, Retiree	\$850	\$925
IC-OS Board Review	\$150	\$150

ce.mayo.edu/cardiooncupdate2026

PROGRAM AT-A-GLANCE

- Intro to Cardio-Oncology: Guideline Based Surveillance Strategy for Chemotherapy Related Cardiotoxicity
- Intro to Cardio-Oncology: Prevention and Management of Chemotherapy Related Cardiotoxicity
- Traditional Cancer Therapies
- Targeted Therapies for Breast Cancer
- Advanced Heart Failure Management in Cardio-Oncology
- Role of Advanced Imaging in Cardio-Oncology
- Artificial Intelligence in Cardio-Oncology: The Future of Risk Stratification and Early Detection
- Updates in Cardio-Oncology 2026: Current State of Cardio-Oncology Practice and Where Do We Go From Here?
- Anticoagulation for PE/DVT in a Cardio-Oncology Setting
- Vegf Inhibitors and Cardiovascular Complications
- Top Publications in Cardio-Oncology 2026
- Tyrosine Kinase Inhibitor Overview
- BTK Inhibitors
- Special Considerations in the Management of ACS in Cancer Patients
- Cardiac Complications of CAR-T Therapy
- Building a Cardio-Oncology Practice
- Cardio-Oncology Education
- Cardio-Vascular Considerations in Cancer Survivorship
- Exercise and Cardiac Rehab for Cancer Patients and Survivors
- Stem Cell Transplant and the Heart
- CHIP
- Prostate Cancer and Heart Disease
- Hormone Therapy and Cardiac Risk in Breast Cancer
- Childhood Survivorship
- Long QT Syndrome
- Radiation Induced Vasculopathy

- Diagnosis and Management of Carcinoid Syndrome
- Novel Therapies for TTR Cardiac Amyloid
- Treatment of AL Amyloid with Cardiac Involvement
- Atrial Fibrillation Management in Cardiac Amyloid
- Specialized Sessions for Advanced Practice Providers
- IC-OS Session
- Case Study Sessions

GUEST FACULTY

Ana Barac, M.D.
Inova Cardiology

Carolyn M Larsen, M.D.
University of Nebraska Medical Center

Jeremy Larsen, M.D.
University of Nebraska Medical Center

Accreditation Statement



In support of improving patient care, Mayo Clinic College of Medicine and Science is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Credit Statements

AMA

Mayo Clinic College of Medicine and Science designates this live activity for a maximum of 21.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ANCC

Mayo Clinic College of Medicine and Science designates this activity for a maximum of 21.25 ANCC contact hours. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

ACPE

Mayo Clinic College of Medicine and Science designates this live activity for a maximum of 21.25 ACPE based contact hours. Participants should only claim credit commensurate with the extent of their participation in the activity.



Other Healthcare Professionals

A record of attendance will be provided to other healthcare professionals for requesting credits in accordance with state nursing boards, specialty societies, or other professional associations.

Mayo Clinic Cardio-Oncology Update 2026

COURSE DIRECTORS

Chadi Ayoub, M.B.B.S., Ph.D.

Joerg Herrmann, M.D.

Lida A. Mina, M.D.

Chris Ray, M.D.

Surbhi Shah, M.B.B.S.



Mayo Clinic
13400 E Shea Blvd
Scottsdale, Arizona 85259

ELECTRONIC SERVICE REQUESTED



NOVEMBER 12-15, 2026

**Caesars Republic Scottsdale, a Hilton Hotel
Scottsdale, Arizona**

ce.mayo.edu/cardiooncupdate2026

NON-PROFIT ORG.
U.S. POSTAGE
PAID
MAYO CLINIC

Mayo Clinic School of Continuous Professional Development
ce.mayo.edu | cme@mayo.edu | 800-323-2688

Imagery is copyright Mayo Clinic, Getty Images, Shutterstock or approved for use.
©2026 Mayo Foundation for Medical Education and Research. MC8300-114BRrev0626

Mayo Clinic Cardio-Oncology Update 2026
Scottsdale, Arizona
November 12 - 15, 2026
All times MST Time Zone
Program subject to change

Thursday, November 12, 2026	
11:15 AM	Registration, Lunch and Exhibits
12:00 PM	Welcome Announcements and Intro to Cardio-Oncology Course Directors (Chris Ray, M.D., Chadi Ayoub, M.B.B.S., Ph.D., and Lida A. Mina, M.D.)
12:15 PM	Road Map to Course Course Directors (Chris Ray, M.D., Chadi Ayoub, M.B.B.S., Ph.D., and Lida A. Mina, M.D.)
12:30 PM	Traditional Cancer Therapies Farah Raheem, Pharm.D., R.Ph., BCOP
12:55 PM	Intro to Cardio-Oncology: Guideline Based Surveillance Strategy for Chemotherapy Related Cardiotoxicity Hector R. Villarraga, M.D.
1:20 PM	Intro to Cardio-Oncology: Prevention and Management of Chemotherapy Related Cardiotoxicity Carolyn M. Larsen, M.D. - Guest Faculty
1:45 PM	Q&A Session All Presenting Faculty
2:10 PM	Exhibits and Break
2:25 PM	Targeted Therapies for Breast Cancer Lida A. Mina, M.D.
2:50 PM	Advanced Heart Failure Management in Cardio-Oncology Brian W. Hardaway, M.D.
3:15 PM	Role of Advanced Imaging in Cardio-Oncology Balaji Tamarappoo, M.D., Ph.D.
3:40 PM	Artificial Intelligence in Cardio-Oncology: The Future of Risk Stratification and Early Detection. Chadi Ayoub, M.B.B.S., Ph.D.
4:05 PM	Q&A Session All Presenting Faculty
4:30 PM	Break (General Session Adjourns)
4:45 PM	IC-OS Session (Optional) Joerg Herrmann, M.D.
6:15 PM	Adjourn

Mayo Clinic Cardio-Oncology Update 2026 (CONT)

All times MST Time Zone

Program subject to change

Friday, November 13, 2026	
7:00 AM	Registration, Breakfast and Exhibits Breakfast Non-CME Product Theatre
7:55 AM	Announcements
8:00 AM	Updates in Cardio-Oncology 2026: Current state of cardio-oncology practice and where do we go from here? Ana Barac, M.D. - Guest Faculty (Keynote)
8:25 AM	Challenging case(s) in the management of Checkpoint Inhibitor Cardiotoxicity Ana Barac, M.D. - Guest Faculty
8:50 AM	Anticoagulation for PE/DVT in a Cardio-Oncology Setting Surbhi Shah, M.B.B.S.
9:15 AM	Vegf Inhibitors and Cardiovascular Complications Christina Wu, M.B., B.Ch., M.D.
9:40 AM	Q&A Session All Presenting Faculty
10:05 AM	Exhibits and Break
10:20 AM	Top publications in Cardio-Oncology 2026 Joerg Herrmann, M.D.
10:45 AM	Tyrosine Kinase Inhibitor Overview Chris Ray, M.D.
11:10 AM	BCR-ABL TKI cardiotoxicity case(s) Joerg Herrmann, M.D.
11:35 AM	BTK Inhibitors Sameer A. Parikh, M.B.B.S.
12:00 PM	Q&A Session All Presenting Faculty
12:25 PM	Lunch and Exhibits Lunch Non-CME Product Theatre
1:25 PM	Special Considerations in the Management of ACS in Cancer Patients Kwan S. Lee, M.B., B.Ch., M.D.
1:50 PM	Cardiac Complications of CAR-T therapy Rafael Fonseca, M.D.
2:15 PM	Hormone Therapy and Cardiac Risk in Breast Cancer Kathryn J. Ruddy, M.D.
2:40 PM	Break (General Session Adjourns)
2:50 PM	IC-OS Session (Optional) Joerg Herrmann, M.D.
4:20 PM	Adjourn

Mayo Clinic Cardio-Oncology Update 2026 (CONT)

All times MST Time Zone

Program subject to change

Saturday, November 14, 2026	
7:00 AM	Registration, Breakfast and Exhibits Breakfast Non-CME Product Theatre
7:55 AM	Announcements
8:00 AM	Track 1: General Session: My experience building a cardio-oncology practice / Track 2: Specialized Sessions for Advanced Practice Provider: Key pearls from building my cardio-oncology practice: an APP perspective Chris Ray, M.D./ Joerg Herrmann, M.D. / Alyssa D. McPherson, APRN, D.N.P.
8:25 AM	Track 1: General Session: Cardio-oncology education / Track 2: Specialized Sessions for Advanced Practice Provider: Introduction to clinical trials research: what you need to know for clinical practice in cardio-oncology Guest Speaker - Daniel Lenihan, M.D. / Elizabeth L. Bechtum, APRN, C.N.P., D.N.P.
8:50 AM	Track 1: General Session: Cardio-vascular considerations in cancer survivorship / Track 2: Specialized Sessions for Advanced Practice Provider: Challenging Cases of Hypertension Management in Cancer patients Alyssa D. McPherson, APRN, D.N.P. / Hema Narayanasamy, M.B.B.S.
9:15 AM	Track 1: General Session: Exercise and Cardiac Rehab for Cancer Patients and Survivors / Track 2: Specialized Sessions for Advanced Practice Provider: Challenging Inpatient Cardio-oncology case(s) Bryan J. Taylor, Ph.D. / Sidney M. Bianco, APRN, D.N.P.
9:40 AM	Track 1: General Session: Question and Answer Session / Track 2: Specialized Sessions for Advanced Practice Provider: Q&A All Presenting Faculty
10:05 AM	Exhibits and Break
10:20 AM	Stem Cell Transplant and the Heart Hassan Alkhateeb, M.D
10:45 AM	CHIP TBD
11:10 AM	Prostate Cancer and Heart Disease Parminder Singh, M.D.
11:35 AM	Pericardial effusion and Pericarditis Case(s) S. Allen Luis, M.B.B.S., Ph.D.
12:00 PM	Q&A Session All Presenting Faculty
12:25 PM	Lunch and Exhibits Lunch Non-CME Product Theatre
1:25 PM	Therapies for the Management of Cardiotoxicity: Practical Perspectives versus Evidence Based Approach? Carolyn M. Larsen, M.D. - Guest Faculty
1:50 PM	Long QT Syndrome Hicham Z. El Masry, M.D.
2:15 PM	Challenging Audience Cases Session Panel Discussion - Chris Ray, M.D., Chadi Ayoub, M.B.B.S., Ph.D., Lida A. Mina, M.D., and Farah Raheem, Pharm.D., R.Ph., BCOP
2:40 PM	Adjourn

Mayo Clinic Cardio-Oncology Update 2026 (CONT)

All times MST Time Zone

Program subject to change

Sunday, November 15, 2026	
7:00 AM	Registration, Breakfast and Exhibits Breakfast Non-CME Product Theatre
7:55 AM	Announcements
8:00 AM	Malignant Cardiac Mass Case(s) Yasmeen M. Butt, M.D.
8:25 AM	Radiation Heart Disease Case(s) Sameer R. Keole, M.D.
8:50 AM	Radiation Induced Vasculopathy George Wang, M.D.
9:15 AM	My approach to the diagnosis and management of carcinoid syndrome Bassam B. Sonbol, M.D.
9:40 AM	Carcinoid Heart Disease Case(s) Chadi Ayoub, M.B.B.S., Ph.D.
10:05 AM	Q&A Session All Presenting Faculty
10:20 AM	Exhibits and Break
10:45 AM	Novel Therapies for TTR Cardiac Amyloid Eric D. Steidley, M.D.
11:10 AM	Treatment of AL amyloid with cardiac involvement Jeremy Larsen, MD - Guest Faculty
11:35 AM	Atrial fibrillation management in Cardiac Amyloid Hicham El Masry, M.D.
12:00 PM	Q&A Session All Presenting Faculty
12:25 PM	Adjourn